Acer Therapeutics is a pharmaceutical company that specializes in acquiring, developing, and commercializing therapies for serious rare and life-threatening diseases with significant unmet medical needs. In the United States, they have received approval for OLPRUVA™ (sodium phenylbutyrate), a treatment for urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). Acer is dedicated to advancing their pipeline of investigational products for rare and life-threatening diseases.

This includes OLPRUVA™ for the treatment of various disorders, including Maple Syrup Urine Disease (MSUD), and EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. With a focus on developing therapies for patients with serious, ultra-rare diseases, Acer Therapeutics is committed to addressing unmet medical needs and improving the lives of those affected. Stay updated with Acer's developments and breakthroughs by visiting their website or subscribing to their newsletter